[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,446
  • Shares Outstanding, K 115,245
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,200 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 0.74
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.80

Options Overview Details

View History
  • Implied Volatility 423.98% (+146.23%)
  • Historical Volatility 52.10%
  • IV Percentile 67%
  • IV Rank 33.71%
  • IV High 1,171.62% on 10/14/25
  • IV Low 43.77% on 03/16/26
  • Expected Move (DTE 34) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 1,901
  • Open Int (30-Day) 1,817
  • Expected Range 1.2100 to 1.2100

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 2
  • High Estimate $-0.06
  • Low Estimate $-0.09
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9563 +26.53%
on 07/10/26
1.2950 -6.56%
on 07/16/26
+0.1500 (+14.15%)
since 06/17/26
3-Month
0.9563 +26.53%
on 07/10/26
1.7100 -29.24%
on 04/22/26
-0.3000 (-19.87%)
since 04/17/26
52-Week
0.8800 +37.50%
on 12/01/25
1.7100 -29.24%
on 04/22/26
+0.0200 (+1.68%)
since 07/17/25

Most Recent Stories

More News
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.

CRDL.TO : 1.69 (-2.87%)
CRDL : 1.2100 (-1.63%)
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion.

CRDL.TO : 1.69 (-2.87%)
CRDL : 1.2100 (-1.63%)
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

TORONTO , July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.69 (-2.87%)
CRDL : 1.2100 (-1.63%)
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

TORONTO , June 25, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.69 (-2.87%)
CRDL : 1.2100 (-1.63%)
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

TORONTO , June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.69 (-2.87%)
CRDL : 1.2100 (-1.63%)
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT

TORONTO , June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.69 (-2.87%)
CRDL : 1.2100 (-1.63%)
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

TORONTO , May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.69 (-2.87%)
CRDL : 1.2100 (-1.63%)
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

TORONTO, ON , May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.69 (-2.87%)
CRDL : 1.2100 (-1.63%)
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

TORONTO, ON , May 7, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.69 (-2.87%)
CRDL : 1.2100 (-1.63%)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

TORONTO , April 28, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.69 (-2.87%)
CRDL : 1.2100 (-1.63%)

Business Summary

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

See More

Key Turning Points

3rd Resistance Point 1.3667
2nd Resistance Point 1.3233
1st Resistance Point 1.2667
Last Price 1.2100
1st Support Level 1.1667
2nd Support Level 1.1233
3rd Support Level 1.0667

See More

52-Week High 1.7100
Fibonacci 61.8% 1.3929
Fibonacci 50% 1.2950
Last Price 1.2100
Fibonacci 38.2% 1.1971
52-Week Low 0.8800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.